Tags : Immunometabolism

Roche Signs an Exclusive Worldwide Option and License Agreement with

Shots: Rhoes to receive $42.5M up front, milestones $90M for specified research and preclinical development plus option fees, $660M milestones based on development, regulatory and sales plus royalties on sales. Roche to get exclusive option to license for defined no. of candidates while Rhoes will conduct research to discover and develop novel candidates in immunometabolism […]Read More